/주식/TNGX
TNGX

TNGX

USD

Tango Therapeutics Inc.

$8.010+0.120 (1.521%)

실시간 가격

Healthcare
생명공학
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$7.890

고가

$8.170

저가

$7.470

거래량

2.98M

기업 기본 정보

시가총액

1.1B

산업

생명공학

국가

United States

거래 통계

평균 거래량

2.68M

거래소

NGM

통화

USD

52주 범위

저가 $1.03현재가 $8.010고가 $9.7

관련 뉴스

GlobeNewswire

Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S.

더 보기
Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Analyst Upgrades

Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $12

Guggenheim analyst Charles Zhu maintains Tango Therapeutics with a Buy and raises the price target from $10 to $12.

더 보기
Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $12
GlobeNewswire

Tango Therapeutics Announces $225 Million Financing

BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines,

더 보기
Tango Therapeutics Announces $225 Million Financing
GlobeNewswire

Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

– 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% – – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49%

더 보기
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers